Introduction {#Sec1}
============

Coronary artery disease (CAD) leads to the death of more than seven million people each year worldwide \[[@CR1]\]. Guidelines for the treatment of CAD strongly encourage the use of optimal medical therapy as a first step in its management \[[@CR2], [@CR3]\]. Percutaneous coronary intervention (PCI) is also frequently used in the management of CAD to relieve symptoms of angina. Registry data suggest that more than half of CAD patients have undergone a PCI, though this figure can vary depending on sex and geographical location \[[@CR4], [@CR5]\].

Angina pectoris is a common symptom of CAD and affects around 112 million people globally \[[@CR6]\]. PCI has been shown to substantially reduce angina symptoms particularly in patients with severe angina \[[@CR7]--[@CR9]\]. However, a randomized clinical study, COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; ClinicalTrials.gov \#NCT00007657), showed that the benefits of PCI regarding quality of life (QoL) can be short term \[[@CR10]\] and that angina symptoms can persist in many patients after PCI \[[@CR11]--[@CR13]\]. In a study including post-myocardial infarction (MI) patients, angina symptoms were reported to have occurred more frequently after 1 year in patients with a clinical history of PCI (25.2%) than in those without (15.4%) \[[@CR13]\]. COURAGE also showed that complementing optimal medical therapy with PCI does not lessen the risk of death, MI, or other major cardiovascular events in comparison to medical therapy alone, and may have no long-term or additional cardiovascular benefits \[[@CR14]\]. More recent meta-analyses of randomized trials comparing PCI and medical therapy in patients with CAD showed that PCI did not reduce the risk of mortality, non-fatal MI, or revascularization \[[@CR15], [@CR16]\]. Two-year results from the FAME II (ClinicalTrials.gov \#NCT01132495) trial showed a significant reduction in urgent revascularizations after fractional flow reserve-guided PCI plus medical therapy compared with medical therapy alone, but also with no significant effect on mortality or MI \[[@CR17]\]. These results may indicate a relevance of objective assessment of ischemia in patients with PCI to improve outcomes.

Optimal medical therapy is currently under-prescribed for symptomatic CAD patients and less than half benefit from such an approach prior to PCI \[[@CR18]\]. One such medical therapy, ivabradine, lowers heart rate by reducing the activity of the cardiac pacemaker through inhibition of the *I*~f~ current, which in turn decreases cardiac workload and myocardial oxygen consumption \[[@CR19]\]. It is effective at reducing ischemia and symptoms of angina \[[@CR20]--[@CR23]\]. The ADDITIONS (PrActical Daily efficacy anD safety of Procoralan^®^ In combinaTION with betablockerS; Controlled-Trials.com \#ISRCTN53233058) trial \[[@CR24]\] showed that treating patients with stable angina with a combination of ivabradine and beta-blocker reduces heart rate, angina attacks, and nitrate consumption and improves Canadian Cardiovascular Society (CCS) classification along with QoL. Due to the fact that angina symptoms can persist in many patients after PCI, leading to significant impairment in QoL \[[@CR10]--[@CR13]\], we aimed to evaluate ivabradine as an option for such patients with high resting heart rate. In this paper, we present a post hoc analysis of ADDITIONS that assesses the effect of ivabradine as part of a medical therapy when treating stable angina in patients with a clinical history of PCI at baseline.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

ADDITIONS was a 4-month, non-interventional, prospective, open-label multicenter trial. A more detailed description of the methods used in the ADDITIONS trial is given by Werdan et al \[[@CR24]\]. A total of 2,330 patients with stable angina pectoris were included in 818 centers in Germany. Investigators, comprising physicians specialized in internal medicine, general practitioners, or cardiologists in private practice, filled out a standardized questionnaire at each visit during the trial.

Patients with symptomatic chronic stable angina pectoris under current beta-blocker therapy were eligible for inclusion into the study. To be suitable for treatment with ivabradine, patients also had to have one of the following: (1) angina pectoris that was insufficiently controlled with beta-blocker alone or (2) insufficient effectiveness of---or intolerance to---another anti-anginal medicine leading to a change in treatment. Only patients who had given their written consent and who met the inclusion and exclusion criteria were eligible for inclusion. Patients commenced ivabradine treatment at 5 mg, twice daily. At the investigator's discretion, after 4 weeks, the dose could be increased to 7.5 mg, twice daily. For patients aged ≥75 years or with resting heart rate \<50 beats per minute (bpm) at follow-up visits, investigators also had the option of prescribing a lower dose of 2.5 mg, twice daily. The physician was free to change the ivabradine dose during the trial if considered necessary.

This study was carried out in accordance with the Declaration of Helsinki and in agreement with the ethical guidelines of the European Independent Ethics Committee. Ethical approval was granted by the ethical commission of Martin-Luther-University Halle-Wittenberg. The ADDITIONS study is registered at [www.controlled-trials.com](http://www.controlled-trials.com) (No. ISRCTN53233058).

Clinical Examinations {#Sec4}
---------------------

There were three visits (at baseline, and around 1 and 4 months after baseline) programmed during this trial. At baseline, parameters including general medical and cardiovascular history (previous MI or revascularization using PCI), cardiac risk factors, concomitant diseases, and medication were recorded. Heart rate, the incidence of angina attacks (within the previous week), and the frequency of use of short-acting nitrates (within the previous week) in patients were documented at baseline and after 1 and 4 months. Patient QoL was also recorded using an EQ-5D questionnaire (single scores summarized using the EQ-5D index score) at each visit \[[@CR25]\]. Information relating to safety such as suspected adverse drug reactions, reasons for discontinuing ivabradine and changes in concomitant medication was recorded after 1 and 4 months. The effectiveness and tolerance of ivabradine was further assessed by the treating physician and categorized into "very good", "good", "moderate", or "poor". Due to the non-interventional design of the study, the participating physicians were free to initiate any intervention they considered appropriate for the individual patient.

Analysis {#Sec5}
--------

In this post hoc analysis of the ADDITIONS population, we divided the population according to whether they had previously had a PCI or not. In the two subgroups, we evaluated the effect of ivabradine on heart rate and assessed its impact upon the incidence of angina attacks, frequency of use of short-acting nitrates, angina classification using the CCS class, and QoL using the EQ-5D index and visual analog scale (VAS) score. The previous PCI subgroup population was also divided according to whether patients had a baseline heart rate of \<70 bpm or ≥70 bpm. The impact of ivabradine on the incidence of angina attacks, frequency of use of short-acting nitrates rate and heart rate in these two subgroups was then evaluated, and the mean daily dose of ivabradine was reported.

Statistics {#Sec6}
----------

The analysis of the data is essentially descriptive and was performed using SAS^®^ software (version 9.1; SAS Institute Inc., Cary, NC, USA). Absolute and relative changes were calculated for continuous variables such as heart rate, number of angina attacks, consumption of short-acting nitrates and EQ-5D score, and described using the arithmetic mean and standard deviation. Details are given in Werdan et al \[[@CR24]\]. Absolute changes of values between baseline and follow-up visits were assessed using Wilcoxon's signed-rank test and Chi-square test. Corresponding *P* values should be interpreted descriptively.

Results {#Sec7}
=======

Baseline {#Sec8}
--------

Of the 2,330 patients who participated in the ADDITIONS study, 11 were not included in this post hoc analysis as their PCI status had not been recorded. Among the 2,319 patients with a recorded PCI status (Table [1](#Tab1){ref-type="table"}), 51.4% had previously had a PCI. Two-thirds (67%) of the patients with PCI were male vs. 49% in patients without PCI. The mean age was 65.8 ± 9.9 years and 66.0 ± 11.5 years in patients with and without a previous PCI, respectively. The majority of patients with previous PCI had only one previous PCI (56%). Patients with a previous PCI status were more likely to have a history of MI, hypertension, dyslipidemia, diabetes, and peripheral artery disease (PAD), but less likely to have chronic obstructive pulmonary disease (COPD) or asthma. The mean resting heart rate was slightly lower in patients with a previous PCI than without (83.1 ± 11.0 bpm vs. 87.0 ± 13.2 bpm, respectively). The number of angina attacks was slightly higher in patients with a PCI status than without (1.9 ± 2.4 vs.1.5 ± 2.0 per week, respectively). A similar trend was observed in the use of nitrates (2.7 ± 3.7 vs. 1.8 ± 2.8 per week, respectively). A lower proportion of patients in the previous PCI subgroup were classified as CCS class I or II (75%), in comparison with the no previous PCI subgroup (86%). At baseline, the EQ-5D scores were similar in patients with and without a previous PCI at 0.65 ± 0.28 and 0.68 ± 0.26, respectively (Table [1](#Tab1){ref-type="table"}). The EQ-5D VAS scores were also comparable at 56.2 ± 18.1 and 58.7 ± 18.5 for previous PCI and no previous PCI, respectively.Table 1Baseline characteristics of the stable CAD population with angina in ADDITIONS according to PCI statusCharacteristicPatients with previous PCI (*n* = 1,193)Patients with no previous PCI (*n* = 1,126)Demographic characteristics Age (years)65.8 ± 9.966.0 ± 11.5 Men803 (67%)547 (49%) Body mass index (kg/m^2^)28.1 ± 4.328.5 ± 4.9Medical history Previous PTCA with stent (PCI)  One669 (56%)--  Two or more311 (26%)--  Unknown213 (18%)-- Previous myocardial infarction681 (58%)157 (13%) Hypertension1,072 (90%)988 (88%) Dyslipidemia889 (75%)638 (57%) Diabetes mellitus409 (34%)368 (33%) Peripheral artery disease125 (10%)79 (7%) COPD171 (14%)173 (15%) Asthma37 (3%)76 (7%)Cardiovascular medication Beta-blockers1,193 (100%)1,126 (100%) ACE inhibitors698 (59%)500 (44%) AT~1~ antagonists341 (29%)319 (28%) Calcium antagonists244 (20%)185 (16%) Long-acting nitrates/molsidomin374 (31%)204 (18%) Ranolazine12 (1%)4 (\<1%) Diuretics477 (40%)398 (35%) Aspirin1,059 (89%)804 (71%) Clopidogrel336 (28%)84 (7%) Statins1,001 (84%)689 (61%)Clinical findings Heart rate (bpm)83.1 ± 11.087.0 ± 13.2 Weekly number of angina attacks1.9 ± 2.41.5 ± 2.0 Weekly use of nitrates2.7 ± 3.71.8 ± 2.8 Systolic blood pressure (mm Hg)135.1 ± 15.1140.0 ± 16.1 Diastolic blood pressure (mm Hg)81.5 ± 9.383.5 ± 9.5 Ejection fraction (%)54.9 ± 12.957.2 ± 12.9Canadian Cardiovascular Society class Class I214 (20%)391 (40%) Class II609 (55%)452 (46%) Class III264 (24%)139 (14%) Class IV12 (1%)4 (\<1%)Quality of life Visual analog scale56.2 ± 18.158.7 ± 18.5 Quality of life index0.65 ± 0.280.68 ± 0.26Values are presented as mean ± standard deviation or numbers and percentages (%)*Bpm* beats per minute, *CAD* coronary artery disease, *COPD* chronic obstructive pulmonary disease, *PCI* percutaneous coronary intervention, *PTCA* percutaneous transluminal coronary angioplasty

Beta**-**Blocker Dosage {#Sec9}
-----------------------

Every patient in the study was prescribed optimal dosages of beta-blocker at the discretion of the investigator. Metoprolol and bisoprolol were prescribed for the majority of patients, at similar rates in the two subgroups (previous PCI, 45% and 36%, respectively; no previous PCI, 41% and 39%, respectively) and at similar doses (previous PCI, 110.6 ± 50.6 mg and 7.2 ± 3.4 mg, respectively; no previous PCI, 101.5 ± 48.9 mg and 6.8 ± 3.5 mg, respectively). Other beta-blockers, which were prescribed for \<13% of patients in each subgroup, in decreasing order of frequency were, nebivolol, carvedilol, and atenolol. The recommended maximum beta-blocker doses were defined for metoprolol at 190 mg/day, bisoprolol and nebivolol each at 10 mg/day, and atenolol and carvedilol each at 100 mg/day. A slightly higher proportion of patients in the previous PCI subgroup (81%) were taking ≥50% to \<100% or ≥100% of the recommended maximum doses in comparison with the no previous PCI group (75%).

Effect of Ivabradine {#Sec10}
--------------------

At baseline, patients with and without a previous PCI were on comparable doses of ivabradine (mean daily dose, 9.6 ± 1.3 mg/day and 9.5 ± 1.6 mg/day, respectively). An initial rapid decrease in heart rate was similarly observed in both subgroups over the first month (Fig. [1](#Fig1){ref-type="fig"}). The heart rate of patients with a previous PCI decreased from 83.1 ± 11.0 bpm to 69.4 ± 8.8 bpm, while the heart rate in patients without a previous PCI dropped from 87.0 ± 13.2 bpm to 72.5 ± 10.6 bpm. The decrease in heart rate was maintained in the 2 subgroups over the study, and the heart rates for the previous PCI and no previous PCI subgroups at 4 months were 64.4 ± 7.6 bpm and 66.8 ± 8.5 bpm, respectively (*P* \< 0.0001 for all changes in both subgroups). The mean daily dose of ivabradine increased in both subgroups over the 4-month study period to 12.6 ± 2.9 mg/day and 12.1 ± 3.0 mg/day for patients with and without a PCI, respectively.Fig. 1Reduction in resting heart rate with initiation of ivabradine in patients with stable angina on top of optimal medical therapy including beta-blockers who underwent previous percutaneous coronary intervention (PCI) and those who did not (No PCI). *P* value describes change between baseline and month 1 and baseline and month 4 for both subgroups. *bpm* beats per minute

The number of angina attacks experienced by patients with a history of PCI was slightly higher at baseline at 1.9 ± 2.4 per week vs. 1.5 ± 2.0 per week in patients without. However, a substantial and similar decrease in the number of weekly angina attacks was observed in both subgroups after 1 month dropping 2.7-fold to 0.7 ± 1.4 and threefold to 0.5 ± 1.1 for the previous PCI and no previous PCI subgroups, respectively (Fig. [2](#Fig2){ref-type="fig"}). By 4 months, the number of angina attacks had further dropped to comparable levels in patients with a PCI (0.3 ± 1.0 attacks per week) and patients without (0.2 ± 0.7 attacks per week; *P* \< 0.0001 for all changes in both subgroups). The drop in the number of angina attacks was reflected by a similar decrease in the use of short-acting nitrates. At baseline, patients with a previous PCI used nitrate more often (2.7 ± 3.7 times per week) than patients without (1.8 ± 2.8 times per week). After 1 month, nitrate usage dropped to 1.0 ± 1.9 and 0.6 ± 1.5 times per week in patients with and without a PCI, respectively (Fig. [2](#Fig2){ref-type="fig"}). The decrease in nitrate usage continued at a comparable rate in both subgroups, so that by 4 months patients with and without a PCI were using nitrates at similar frequencies, 0.5 ± 1.5 and 0.3 ± 1.0 times per week (*P* \< 0.0001 for all changes in both subgroups).Fig. 2Number of angina attacks (**a**) and use of short-acting nitrates (**b**) per week in post-PCI and no PCI stable angina patients. *P* value describes change between baseline and month 1 and baseline and month 4 for both subgroups. *PCI* percutaneous coronary intervention

The severity of angina was also assessed in both groups using the CCS scale. At baseline, twice the number of patients without a previous PCI (39.7%) had CCS class I angina than patients with a previous PCI (19.5%; Fig. [3](#Fig3){ref-type="fig"}). Most patients were in CCS class II angina (55.4% with a PCI and 45.8% without). After 4 months of treatment, there was a substantial shift of patients to CCS class I in both subgroups from 19.5% to 65.2% in patients with a PCI and 39.7% to 71.1% in patients without. Notably, the combined proportion of patients in the previous PCI subgroup who moved into CCS class III and IV dropped by 21.2% after 4 months in comparison with an 11.1% drop in the no previous PCI subgroup (*P* \< 0.0001 for changes in each CCS Class).Fig. 3Change in severity of angina from baseline to 4 months, according to CCS class, in post-PCI and no PCI stable angina patients. *P* value describes the change between baseline and month 1 (data not shown) and baseline and month 4 for each CCS class. *CCS* Canadian cardiovascular society, *PCI* percutaneous coronary intervention

After 4 months, the EQ-5D score indicated that patient QoL had improved in both subgroups increasing from 0.65 ± 0.28 to 0.83 ± 0.20 in patients with a previous PCI and 0.68 ± 0.26 to 0.82 ± 0.20 for patients without (*P* \< 0.0001 for all changes in both subgroups; Fig. [4](#Fig4){ref-type="fig"}). QoL improved slightly more in the previous PCI subgroup (27.8%) than in the no previous PCI group (21.9%). The final VAS scores indicated an improvement in QoL in all patients with slightly better improvement in scores in patients with a previous PCI (28.7%) vs. those without (24.5%; 56.2 ± 18.1 to 72.3 ± 15.2 vs. 58.7 ± 18.5 to 73.1 ± 15.6, respectively).Fig. 4Change in quality of life index (EQ-5d) (**a**) and EQ-5d visual analog scale score (**b**) in post-PCI and no PCI stable angina patients. *P* value describes change between baseline and month 1 and baseline and month 4 for both subgroups. *PCI* percutaneous coronary intervention, *VAS* Visual analog scale

The efficacy of ivabradine in patients with a baseline heart rate of \<70 bpm vs. ≥70 bpm, in terms of the absolute and relative reduction in the frequency of angina attacks, nitrate consumption, and heart rate, was also evaluated. In the previous PCI subgroup, patients with a baseline heart rate ≥70 bpm had similar absolute decrease in angina attacks at month 1 (−1.3 ± 1.7 vs. −1.1 ± 2.4 per week) and month 4 (−1.6 ± 1.9 vs. −1.7 ± 2.9 per week) than those with a baseline heart rate \<70 bpm (Table [2](#Tab2){ref-type="table"}). However, there was a more pronounced absolute reduction in the use of nitrates per week at month 4 for patients with a baseline heart rate of ≥70 bpm than those with a baseline heart rate of \<70 bpm (−2.3 ± 3.1 vs. −1.7 ± 5.0). There was a large difference in the absolute change in heart rate for patients with a baseline heart rate of ≥70 bpm vs. \<70 bpm at month 1 (−14.6 ± 8.7 vs. −2.9 ± 7.3 bpm) and at month 4 (−19.9 ± 9.8 vs. −5.0 ± 6.9 bpm). Patients with a baseline heart rate of ≥70 bpm were on a higher daily dose of ivabradine (12.7 ± 2.8 mg) during the study than patients with a baseline heart rate of \<70 bpm (10.9 ± 2.8 mg). There was a greater relative reduction in the number of angina attacks per week in patients with a baseline heart ≥70 bpm in comparison with patients who had a baseline heart rate of \<70 bpm at month 1 (70.7% vs. 49.2%) and at month 4 (87.5% vs. 67.0%; Fig. [5](#Fig5){ref-type="fig"}). A larger relative reduction in weekly nitrate consumption was also observed for patients with a baseline heart rate ≥70 bpm vs. \<70 bpm at month 1 (70.0% vs. 57.3%) and 4 (86.9% vs. 60.7%). Patients with a baseline heart rate ≥70 bpm also had a considerably greater relative reduction in heart rate than patients with a baseline heart rate of \<70 bpm at month 1 (16.8% vs.4.1%) and month 4 (22.9% vs. 7.3%).Table 2Absolute reduction in angina attacks, nitrate use, and heart rate and mean daily ivabradine dose in the previous PCI subgroup according to patient baseline heart rateAbsolute reductionBaseline heart rate\<70 bpm (*n* = 94)≥70 bpm (*n* = 1,095)Angina attacks (per week) Month 1−1.1 ± 2.4\
*n* = 85−1.3 ± 1.7\
*n* = 1,006 Month 4−1.7 ± 2.9\
*n* = 85−1.6 ± 1.9\
*n* = 970Nitrate use (per week) Month 1−1.6 ± 3.8\
*n* = 83−1.8 ± 2.6\
*n* = 987 Month 4−1.7 ± 5.0\
*n* = 82−2.3 ± 3.1\
*n* = 956Heart rate Month 1−2.9 ± 7.3\
*n* = 93−14.6 ± 8.7\
*n* = 1,087 Month 4−5.0 ± 6.9\
*n* = 91−19.9 ± 9.8\
*n* = 1,073Daily ivabradine dose (mg) Month 110.7 ± 2.8\
*n* = 9112.7 ± 2.8\
*n* = 1,073 Month 410.9 ± 2.8\
*n* = 8812.7 ± 2.8\
*n* = 1,057Values are presented as mean ± standard deviation*bpm* beat per minute, *PCI* percutaneous coronary interventionFig. 5Relative reduction in the number of angina attacks per week (**a**) and use of short-acting nitrates (**b**) per week and heart rate (**c**) in patients with stable angina in the post-PCI group according to baseline heart rate. *PCI* percutaneous coronary intervention

Investigators Assessment {#Sec11}
------------------------

The effectiveness and tolerability of ivabradine were assessed as either "very good" or "good" by treating physicians for over 96% of all patients. No differences in either effectiveness or tolerability were observed by the physicians between the two subgroups (Table [3](#Tab3){ref-type="table"}). For the majority of patients with and without a previous PCI (97.8% and 96.6%, respectively), treating physicians categorized ivabradine effectiveness as either "very good" or "good". Similarly, physicians classified ivabradine tolerability as either "very good" or "good" for over 99% of patients in each of the two subgroups.Table 3Physician assessment of the effectiveness and tolerability of ivabradine after 4 months in the ADDITIONS population, according to PCI statusIvabradinePatients with previous PCI (*n* = 1,193)Patients with no previous PCI (*n* = 1,126)Effectiveness1,170 (98%)1,109 (98%) Very good732 (63%)662 (60%) Good412 (35%)409 (37%) Moderate25 (2%)36 (3%) Bad1 (\< 1%)2 (\< 1%)Tolerability1,136 (95%)1,065 (95%) Very good805 (71%)768 (72%) Good328 (29%)295 (28%) Moderate2 (\< 1%)2 (\< 1%) Bad1 (\< 1%)0 (0%)Values are patient numbers and percentages (%)*PCI* percutaneous coronary intervention

Safety {#Sec12}
------

Fourteen patients (0.6%; see Table [4](#Tab4){ref-type="table"} for subgroup data) experienced an adverse drug reaction during the 4-month study period in the total cohort, the most common of which were the presence of phosphenes in the eye (0.13%) and dizziness (0.13%). Other reported adverse drug reactions were palpitations (0.09%), headaches (0.04%), and bradycardia (0.04%). There were no reported cases of death or non-fatal MI. No serious adverse drug reactions were reported during the study.Table 4The most frequently reported adverse drug reactions, according to PCI status, classified using MedDRA (Medical Dictionary for Regulatory Activities)Adverse drug reactionPatients with previous PCI (*n* = 1,193)Patients with no previous PCI (*n* = 1,126)All10 (0.8%)4 (0.4%)Phosphenes (visual symptoms)3 (0.3%)0 (0.0%)Dizziness0 (0.0%)3 (0.3%)Palpitations1 (0.1%)1 (0.1%)Bradycardia1 (0.1%)0 (0.0%)Values are patient numbers and percentages (%)*PCI* percutaneous coronary intervention

Discussion {#Sec13}
==========

This analysis has shown that treating stable angina pectoris patients with a combination of ivabradine and beta-blockers lowered heart rate and reduced the frequency of angina symptoms to the extent that CCS classification and QoL improved independently of PCI status (*P* \< 0.0001 for all changes). Ivabradine was well tolerated by patients in both subgroups. These results are consistent with the findings of a pooled analysis of randomized trials assessing the effect of ivabradine in various subpopulations of angina pectoris patients including those with a previous PCI \[[@CR26]\].

PCI alleviates symptoms of angina by a local approach, as it directly removes defined, hemodynamically compromising lesions \[[@CR27]\]. It has an important role to play in the treatment of lifestyle-limiting angina \[[@CR28]\]. However, as our results indicate, angina symptoms can recur in a large proportion (51%) of post-PCI patients \[[@CR24]\]. In this study, 26% of the previous PCI group had received 2 or more stents and despite this they still suffered symptoms of angina. Recurrent symptoms were also reported in a study in a Swedish population where more than half of the women and a third of the men experienced angina symptoms 4 years after undergoing a PCI \[[@CR12]\]. This was also confirmed by findings from the COURAGE trial, where 41% of patients had angina 3 years after PCI treatment \[[@CR10]\].

As CAD is a diffuse disease process, frequently involving the entire coronary vasculature, it is more likely to benefit from systemic treatments such as medical therapy \[[@CR29]\]. This, combined with the fact that PCI does not lessen the risk of death or other cardiovascular outcomes in comparison with medical therapy alone \[[@CR14]\], suggests that optimal medical therapy for the treatment of stable angina should be pursued from the outset \[[@CR14], [@CR18], [@CR30]\] and is a course of action for symptom control currently recommended by the European and American guidelines for the treatment of CAD \[[@CR2], [@CR3]\].

Heart rate is now believed to have a fundamental role in ischemia and angina. An elevated heart rate increases myocardial oxygen demand and reduces diastolic time, these effects can limit myocardial perfusion leading to ischemia and, in turn, triggering angina \[[@CR20], [@CR31]\]. In patients with stable CAD, an elevated mean heart rate often precedes myocardial ischemia and is associated with a higher risk of cardiovascular events \[[@CR32]--[@CR34]\]. Therefore, medical therapies that effectively reduce heart rate merit serious consideration, but are currently under-prescribed in the treatment of CAD and stable angina \[[@CR35]\].

Ivabradine reduces heart rate by specifically inhibiting the *I*~f~ current, but does not affect blood pressure or other cardiac parameters. In reducing heart rate, ivabradine leads to a decrease in myocardial oxygen consumption and an increase in myocardial perfusion, thereby improving cardiac efficiency \[[@CR36]\]. Furthermore, ivabradine maintains the coronary vasodilation that occurs during exercise \[[@CR37]\]. The results of a placebo-controlled randomized study showed that ivabradine improves coronary collateral function in patients with stable CAD, which was accompanied by diminished ECG signs of ischemia \[[@CR38]\]. In contrast, beta-blockers---owing to their negative effect on myocardial contractility---prolong systole, reducing their beneficial effect on diastolic time. Beta-blockers may also affect vasomotion in the coronary circulation by unmasking alpha-adrenergic vasoconstriction resulting in constriction of large and small coronary arteries during exercise \[[@CR39]\]. Ivabradine has been shown to be an effective anti-anginal agent either as a stand-alone or as a combination therapy including beta-blockers \[[@CR21], [@CR40]\]. Despite the fact that several guidelines recommend a target heart rate below 60 bpm in patients with angina \[[@CR2], [@CR3]\], the CLARIFY (Controlled-Trials.com \#ISRCTN43070564) registry revealed that only 22% of angina patients on beta-blockers achieved an optimal heart rate. Thus, many patients with still elevated heart rate could benefit from the addition of ivabradine to their treatment \[[@CR41]\].

In the ADDITIONS study, the addition of ivabradine led to a further substantial reduction in resting heart rate without excessive bradycardia. The effect was significant within the first 4 weeks of treatment despite prior and ongoing beta-blocker therapy. The effect of ivabradine was more pronounced in patients who had a baseline heart rate of ≥70 bpm. The relative reduction in the number of angina attacks and short-acting nitrate consumption was substantially larger in patients with a baseline heart rate of ≥70 bpm than \<70 bpm at 1 month and 4 months. These data are in line with the pharmacological use-dependent properties of ivabradine, and therefore patients with a higher heart rate will benefit most from therapy with ivabradine \[[@CR42]\]. This is also in line with new recommendations from the European Medicines Agency (EMA) to initiate ivabradine therapy in patients with angina with a heart rate of ≥70 bpm.

QoL has been shown to be worse in patients with stable angina than in those without \[[@CR43]\]. In this post hoc analysis, treatment with ivabradine was associated with improved QoL in patients with stable angina. The CADENCE (Coronary Artery Disease in General Practice; ANZCTR.org.au \#ACTRN12608000347369) study reported that 29% of stable angina patients experienced weekly angina (≥1 episode per week) and had a poorer QoL than patients who experienced angina less than once a week \[[@CR44]\]. These results correlate with our findings where the mean frequency of angina attacks dropped from \>1 to \<1 attack per week and patient QoL improved congruently. QoL is an important factor to be kept in mind when assessing the effectiveness of CAD treatment. The Society of Cardiovascular Angiography recommends that QoL be considered as an outcome in clinical trials and physicians care \[[@CR45]\]. While PCI improves patient QoL in the short term, it is often proportional to the severity of angina symptoms and there is less evidence supporting the benefits of PCI in the presence of severe comorbidities \[[@CR45]\]. The results of this post hoc analysis of ADDITIONS have demonstrated that combining ivabradine with beta-blocker in daily clinical practice reduces symptoms, improves CCS classification and also the QoL in patients with stable angina pectoris after PCI.

The recent data from the SIGNIFY (Study assessInG the morbidity--mortality beNefits of the I*f* inhibitor ivabradine in patients with coronarY artery disease, Controlled-Trials.com \#ISRCTN61576291) trial, conducted in patients with CAD on optimal medical treatment without clinical heart failure, did not demonstrate an effect of ivabradine on the incidence of the primary combined endpoint of cardiovascular death and non-fatal MI \[[@CR46]\]. In a pre-specified subgroup of symptomatic angina patients, there was a small, but statistically significant, increase in the incidence of the primary endpoint with no significant effects for the individual components of the primary endpoint. The incidence of bradycardia was the highest ever reported in any ivabradine trial (ivabradine, 18.0% vs. placebo, 2.3%; *P* \< 0.001). However, in the SIGNIFY trial a therapeutic regimen that is not approved for clinical use was applied, which included a higher initiation and uptitration dose (7.5 and 10 mg bid, respectively). The EMA conducted a review of ivabradine and made recommendations aimed at reducing the risk when using ivabradine in patients with angina. These recommendations included the importance of respecting the recommended dosage regimen---the starting dose should not exceed 5 mg, twice daily, and the maximum dose should not exceed 7.5 mg, twice daily. Furthermore, ivabradine should only be prescribed for patients with a resting heart rate of ≥70 bpm, with a contraindication for the concomitant use of ivabradine with diltiazem or verapamil \[[@CR47]\].

Regarding the safety profile of ivabradine in our study, only mild adverse drug reactions were reported in 0.6% of all patients. There were no reported cases of death, non-fatal MI or serious adverse drug reactions during the study.

A limitation of the study was its short duration (4 months) and that it was open label. There was also no placebo group to support the observed effect of treatment. Adherence to the treatment was not formally evaluated, though the significant reduction in heart rate observed throughout the study indicates good adherence. The frequency of weekly angina attacks and nitrate consumption was measured for only 1 week prior to the study visits. This was due, in part, to the non-interventional design of the study but also to avoid poor or inaccurate symptom recall by patients, which could occur over a longer period of time. Nevertheless, reporting/recall bias to some extent cannot be ruled out, but this may in part also be compensated using different measures of effectiveness (number of attacks, nitrate use, QoL). The missing placebo group, presence of possible reporting bias, and also relatively high resting heart rate at baseline in both patient groups (ivabradine effects are more pronounced with higher heart rate) can lead to an overestimation of the treatment benefit. On the other hand, ivabradine is often used in these high heart rates in practice, thus reflecting current clinical use of the compound. Only half of the patients were uptitrated to the recommended maximal dose (7.5 mg twice daily). Although it is not possible to say to which extent the symptomatic benefit may have increased in this study population by intensified uptitration, it has been demonstrated that heart rate lowering and anti-anginal effects of ivabradine are clearly dose dependent up to 7.5 mg twice daily \[[@CR20]\]. Another limitation of the study regarding specifically the sub-analysis of patients with PCI according to baseline heart rate (\<70 bpm or ≥70 bpm) is the small number of patients with baseline heart rate \<70 bpm (*n* = 94). But it should be noted that ivabradine is not to be used in angina patients with baseline heart rate below 70 bpm according to recent EMA recommendations and European Union indication. Focus of this analysis is therefore clearly the patient cohort with heart rate ≥70 bpm. The main strength of this study was that it was undertaken in a large population of stable angina patients, who were already receiving optimized medical therapy, in over 800 centers in Germany. Moreover, the non-interventional study design supported an evaluation of treatment effects under conditions of routine clinical practice, taking into account patient subgroups that are usually excluded from clinical trials, such as elderly patients or patients with multiple comorbidities.

Conclusions {#Sec14}
===========

The addition of ivabradine to medical therapy, including beta-blockers, for the treatment of stable angina was effective and well tolerated, independent of PCI status. Many patients with a previous PCI have recurring symptoms of angina. Ivabradine should be considered as an important therapeutical option in the treatment of symptomatic stable angina as it reduced the frequency of weekly angina attacks and nitrate usage, led to an improvement in CCS class and a substantial improvement in the QoL of patients with stable angina.
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